ProTmune is under clinical development by Fate Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect ProTmune’s likelihood of approval (LoA) and phase transition for Lymphoblastic Lymphoma took place on 03 Jul 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ProTmune Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

ProTmune overview

ProTmune is under development for the prevention of hematologic malignancies including acute myeloid leukemia, acute lymphoblastic leukemia, T lymphoblastic lymphoma, chronic myelogenous leukemia and myelodysplastic syndrome. It is administered as an intravenous infusion. It is a programmed mobilized peripheral blood therapeutic containing allogeneic peripheral blood mononuclear cells incubated ex vivo with 16, 16-dimethyl prostaglandin E2 and dexamethasone ex vivo with two small molecules (FT1050 and FT4145). It is administered through intravenous infusion.

Fate Therapeutics overview

Fate Therapeutics is a biopharmaceutical company that develops programmed cellular therapies for cancer and immune disorders. The company’s pipeline includes various off-the-shelf, iPSC-derived cellular immunotherapies for the treatment of several hematological malignancies and advanced solid tumors. Its pipeline also includes a donor-derived cell product candidate for the treatment of hematological malignancies. Fate uses its proprietary human-induced pluripotent stem cell (iPSC) platform for product development. The company also has research collaborations with companies, academic centers, and medical centers for the advancement of products and technologies. Fate Therapeutics is headquartered in San Diego, California, the US.

Quick View ProTmune LOA Data

Report Segments
  • Innovator
Drug Name
  • ProTmune
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Immunology
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.